BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore a murine model of BCR/ABL induced CML failed to manifest in the absence of 5-LO, while pharmacological inhibition of 5-LO function in combination with BCR-ABL kinase inhibitor imatinib significantly prolonged survival of CML mice [81].